• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Eko’s AI Algorithm Validated as a Clinical Tool for Detecting Heart Murmurs

Share:

May 14, 2021

What You Should Know:

– Eko, a cardiopulmonary digital health company, today announced the peer-reviewed publication of a clinical study that found that the Eko artificial intelligence (AI) algorithm for detecting heart murmurs is accurate and reliable, with comparable performance to that of an expert cardiologist.

– The findings suggest the utility of the FDA-cleared Eko AI algorithm as a front-line clinical tool to aid clinicians in screening for cardiac murmurs that may be caused by valvular heart disease.

Clinical Study Findings/Results

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Algorithm performance for detecting murmurs was found to have a sensitivity of 90.0% and specificity of 91.4% when excluding grade 1 murmurs which are difficult to hear. The NIH-sponsored, multi-site study published in the Journal of the American Heart Association was the largest study on AI analysis of cardiac murmurs. Study investigators included collaborators from Northwestern Memorial Hospital, University of California San Francisco Medical Center, Los Alamitos Cardiology Clinic, and Mount Sinai Medical Center.

For moderate-to-severe aortic stenosis, the algorithm was found to have a sensitivity of 93.2% and specificity of 86.0%. The algorithm significantly outperformed general practitioners listening for moderate-to-severe valvular heart disease, as a 2018 study showed general practitioners had a sensitivity of 44% and specificity of 69%.

“We are thrilled by how Eko’s digital stethoscopes with Eko AI analysis can help any frontline provider discover meaningful, clinically important cardiac murmurs at the point of care,” said Dr. Adam Saltman, chief medical officer at Eko. “By detecting heart disease earlier, patients can be treated earlier. Costs are typically lower, outcomes are better, and they are more likely to retain a better quality of life. Appropriate patients can be referred to specialists for care when they need it. In addition, the high specificities mean that healthy patients will be much less likely to have unnecessary testing.”

Source: Hitconsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Sartorius Closes Acquisition of Selected Assets of Danaher Life SciencesSartorius Closes Acquisition of Selected Assets of Danaher Life Sciences
  • ImaginAB Announces Extension of Long-Standing Partnership with Boehringer IngelheimImaginAB Announces Extension of Long-Standing Partnership with Boehringer Ingelheim
  • Dermatology Data Sets Lack Ethnicity, Skin Type InformationDermatology Data Sets Lack Ethnicity, Skin Type Information
  • Adicet Announces Completion of Merger with resTORbioAdicet Announces Completion of Merger with resTORbio
  • Athenahealth shares recover losses on report it may receive a late offerAthenahealth shares recover losses on report it may receive a late offer
  • Symplr Closes Acquisition Of ComplyTrackSymplr Closes Acquisition Of ComplyTrack
  • MedAnswers Raises $5 Million Seed Round and Launches First Social Media Feed with Scientifically and Clinically Validated Fertility Resources On The FertilityAnswers AppMedAnswers Raises $5 Million Seed Round and Launches First Social Media Feed with Scientifically and Clinically Validated Fertility Resources On The FertilityAnswers App
  • ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine, Bringing Enhanced and Unmatched Pharmacovigilance Capabilities to Life Sciences IndustryArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine, Bringing Enhanced and Unmatched Pharmacovigilance Capabilities to Life Sciences Industry

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications